Talent Biomedical received registration certificates from Turkish Ministry of Health for Automatic IHC stainer and IHC detection system on August, 2024. It’s a big milestone which will greatly help Talent Biomedical to develop Turkish IHC market. Prior to this, these two products also received NMPA approval in 2018 and CE certification in 2023. Talent Biomedical will continue to research and develop pathological products with high performance, to serve the global market needs in pathological field. About Talent Biomedical In 2017, Talent Biomedical was founded by Dr. Guo who among the first few pioneers in developing polymer IHC detection systems, had been engaging in pathological diagnosis research for more than 30 years. Through 7 years of development, Talent Biomedical has world class IHC polymer detection system and “high throughput automatic stainer (whole staining process of 144 slides only takes around 3 hours)”, in addition, Talent Biomedical developed more than 300 primary antibodies, as well as ISH products, suitable for clinical IHC applications. For more information, please visit www.talentdiagnostics.com.

On 11 December 2023, Talent Biomedical received CE certification for Automatic IHC stainer and related reagents. It will greatly help Talent Biomedical to access to markets overseas.  As for in vitro diagnostic products, getting CE certification proves that the products have been rigorously audited and assessed to compliance with the European regulations of technical, safety and performance requirements, as well as other requirements for in vitro diagnostic products. Talent Biomedical will continue to lead with technological innovation, fully leveraging the advantages of sound quality system, continue to focus on the field of IHC products, develop innovative and compliant diagnostic tools based on clinical needs to serve patients worldwide.   About Talent Biomedical In 2017, Talent Biomedical was founded by Dr. Guo who among the first few pioneers in developing polymer IHC detection systems, had been engaging in pathological diagnosis research for more than 30 years. Through 7 years of development, Talent Biomedical has world class IHC polymer detection system and “high throughput automatic stainer (whole staining process of 144 slides only takes around 3.5 hours)”, in addition, Talent Biomedical developed more than 300 primary antibodies, as well as ISH products, suitable for clinical IHC applications. For more information, please visit www.talentdiagnostics.com.

On May 10th, 2022, Talent Biomedical was proud to announce that we had completed the certification process for ISO 13485. ISO 13485 is a set of standards that define and control quality management system of company, specifically for the manufacturing of medical devices and other health-related products. Although it’s not a specific license for any medical device, it is a clear demonstration of a supplier’s accountability and conformance to industry best practices when making components that are essential for safeguarding human health.

On June 29th, 2018, as a rapidly-growing IVD company specialized in pathological diagnostics with a focus on immunohistochemical (IHC), Talent announced the availability of 257 primary antibodies marked NMPA. These primary antibodies can be used for differential diagnosis of tumors, such as Lung Cancer, Gastric Cancer, Colorectal Cancer, and Gynecological Tumor. Talent was founded by Dr. Guo on Dec. 2017. Based on 30 years study on pathology, Dr. Guo had been developed 257 primary antibodies successfully within 6 months, which can be integrated with “Grape-cluster” Compact Secondary Antibody and High-throughput Automatic Stainer to form a full set of capabilities for building IHC solutions for customers. Part of primary antibodies approved by NMPA: CD2，Calretinin，CD1a，CD3，CD4，CD10，CD15，CD19，CD5，CD8，Chromogranin，CXCL-13，D2-40，Desmin，DOG1，E-Cadherin，EGFR，EMA，FLI-1，IgD，AACT，ACTH，ALK，bcl-6，CA125，Beta-catenin，CA19-9，Calcitonin，Caldesmon，Calponin，CD23，CD30，CD31，CD34，Mammaglobin，MC，MDM2，MLH1，MOC-31，MSH2，MSH6，MUM1，Myelin Basic Protein，Myeloperoxidase，Myo D1，Myoglobin，Napsin A，nm23，NSE，Vimentin，GATA3，CD45，CD56，CD68，CD79a，CDX-2，CEA，Galectin-3，GCDFP-15，Glypican 3，Granzyme B，GST-π，Hepatocyte，HMB-45，HSA，FSH，IDH-1，Ki-67，LEF-1，LRP，Luteinizing Hormone，p16，p120，p40，p53，p63，Pax-5，PSAP，PSA，PSMA，PTH，S100，SMA，Synaptophysin，TdT，Thyroid Stimulating Hormone，TPO，Villin，WT1，TTF-1，GFAP，CK5&6，CK7，CK8&18，CK8，Actin, Alpha Smooth Muscle，AE1/AE3，AMACR/p504s，34Beta E，Cyclin D1，Inhibin, alpha，MART-1/melan A，PRL，CK-L，CK-H，CK10，CK14，CK17，CK18，CK19，CK20，CAM 5.2，AAT，Actin，Alpha-1-Fetoprotein，Annexin A1，ATRX，B72.3，Bax，Ber-EP4，b-FGF，BRAF，BRST2，C4d，CA IX，CD13，CD14，CD123，CD21，CD35，CD38，CD7，bcl-2，CD138，CD43，CD163，C-MET，c-MYC，ERCC1，Helicobacter phlori，IgG4，P21/WAF1，PMS2，p27，Pax-8，SOX-2，CK（pan），Collagen Type IV，COX-2，Ep-CAM，ER-Beta，ESA，Factor VIII Receptor，Fascin，Fibronectin，FOX A1，FOXP1，Gastrin，GLUT-1，Glutamine Synthetase，Glycophorin A，HLA-DR，IgG，NF KAPPA B/P50，OCT3/4，PCNA，PC，PLAP，Podoplanin，Protein Gene Product9.5，pS2，PTEN，Rb Gene Protein，CD141，CD44，CD45RO，CD45R，CD57，CD61，CD63，CD71，CD74，CD99，HNF1-Beta，Human Chorionic，Human Growth Hormone，Human Placental Lactogen，IgA，IgM，IMP3，Insulin，Kappa，Ksp-Cadherin，Lambda，Laminin，Langerin，MUC2，MUC5AC，MUC6，Nestin，NeuN，Neurofilament，NGFR，Oct2，HIF-1α，LMO2，Lysozyme，MRP3，MUC-1，OCT4，Oligo-2，p57，Papilloma Virus，Pax-2，Renal Cell Carcinoma Marker，RRM1，S100P，SALL4，SDHB，Smooth Muscle Myosin，SOX-11，Surfactant Protein B，TFE3，THY，TIA-1，TLE1，TOP2A，Tryptase，Tyrosinase，VEGF，ZAP-70，β-tubulin-III

On January 29th, 2018, exploring the endless journey of immunohistochemical, Talent released and introduced our brand new products to the global users, which are the innovative “Grape-cluster” Compact Secondary Antibody . Comparing with the last generation product which was acquired by a German giant in 2006, the new generation Secondary Antibody has several features: more density of polymers, smaller volume, higher penetrability in cell and tissue. The brand new product has excellent performance in IHC and ISH staining. The first generation polymer,“Chain-cluster” Compact Secondary Antibody ,was a great invention from the founder of Talent, Dr.Guo, who took advantage of it to start his first company in USA, 2003. With great performance, the polymer was widely recognized and accepted by market very soon.

On February 5th, 2018, Talent is a rapidly-growing IVD company specialized in pathological diagnostics with a focus on immunohistochemical(IHC), today announced the availability of a newly redesigned High-throughput Automatic Stainer for IHC, ISH and H&E staining. Since entering the field, Talent has been dedicated to developing a unique Automatic Stainer which has features of high-throughput and excellent-performance. This brand new 2nd generation of automatic stainer retains all the advantages of the previous generation while adding several new features.

On January 29th, 2019, as a rapidly-growing IVD company specialized in pathological diagnostics with a focus on immunohistochemical (IHC), Talent announced the availability of 102 primary antibodies marked NMPA. Together with 257 primary antibodies approved 6 months before, Talent already had a complete product list of 359 reagents which could meet nearly all needs from pathology laboratory. Part of primary antibodies approved this batch: AR，Arginase-1，BRCA1，HBsAg，HBcAg，CDK4，CK5，HHV-8，HPV16，MMP-9，Myogenin，Melanoma，H3K27M，H3K27Me3，PD-1，Bob.1，CD146，CD44v6，LMP-1，MUC-4，SOX-10， MGMT，INI-1，Stathmin，STAT6，PHH3，SATB2，Skeletal Myosin，Survivin，Uroplakin Ⅲ，Brdu，CD45RA，ERG， Factor XⅢ A，MHA，T-PIT，PIT-1，CD44(v6)，Thymidylate Synthase，Cathepsin D，DPC4，HSP27，SSTR 2，Fibrinogen，Perforin，Cadherin 17，MiTF，Uroplakin Ⅱ，Surfactant Protein A，PSCA，TG，DYS1，DYS2，NKX2.2，Brachyury，Caveolin-1，CK 10＆13），Osteopontin，VEGFR2，MDR-1，NKX3.1，CD42b， HGAL，MASH1，LIN28， TRIM29，FH，Digoxin，Cytomegalovirus，SF-1，CD33，MYB，FOXL2，SOX-9，SMARCA4 ，BCL-10，CLaudin 7，HSP70），H3.3G34W，NUT，CLaudin 18.2，H3.3G34R，Helicobacter phlori，H3.3G34V，Fibrinogen-FITC，IgA-FITC，IgG-FITC，IgM-FITC，C1q-FITC，C3c-FITC，C4c-FITC，NTRK，INSM1